Recombinant human EPO (rHuEPO) is currently used in clinical applications for the treatment of anemia associated with chronic renal failure4, 5, as well as for alleviating chemotherapy or radiotherapy-induced anemia in certain cancer patients6. This evidence concerns the gene EPO and anemia (phenotype).